Fulgent Genetics, Temple City, Calif, is offering end-to-end processing, analysis, and reporting for its recently launched covid-19 tests. The company is currently accepting samples directly to its BSL-2 certified lab, which has the capacity to accept and process thousands of samples per day for covid-19 testing alone. End-to-end testing for covid-19 enables Fulgent to more efficiently manage the demand it is seeing for both its RT-PCR and next-generation sequencing (NGS) tests for the virus.
“Fulgent’s proprietary and flexible technology platform has enabled us to rapidly pivot our resources amid the need for covid-19 testing solutions, and we have been able to apply our experience and know-how to help meet testing needs during this pandemic,” says Brandon Perthuis, Fulgent’s chief commercial officer. “Rapid turnaround time has also been crucial in effective testing for covid-19, and over the few weeks that Fulgent has offered testing, over 95% of our reports have been delivered to providers within 24 hours, and many have been delivered within the same day.”
In conjunction with the new tests, Fulgent has also launched a new Web-based portal for the delivery of covid-19 test results. The portal has been customized to make it easy for physicians to access their results across multiple platforms, and it allows them to track samples in progress to quickly determine whether results are positive, negative, or indeterminate.
Fulgent has submitted several covid-19 tests to FDA for emergency use authorization and is currently awaiting responses. The company has received temporary approval from the State of New York to perform covid-19 testing on specimens from New York.
For more information, visit Fulgent Genetics.
Featured image: Colorized scanning electron micrograph of an apoptotic cell (blue) heavily infected with SARS-CoV-2 virus particles (yellow), isolated from a patient sample. Image captured and color-enhanced at the NIAID Integrated Research Facility in Fort Detrick, Md. Photo courtesy NIAID.